Dermatology Industry on Brink of New Era as Competition Heats Up
The dermatology industry is on the cusp of a new era as competition in atopic dermatitis and psoriasis treatment heats up. Developers are under pressure to differentiate their products, accelerate development timelines, and identify new targets beyond current therapies.
The 10th Dermatology Drug Development Summit brings together over 90 leaders from companies such as AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics, and more. The meeting covers various aspects of dermatology innovation, including discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions.
The summit offers a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline. This year's expanded program explores the future of dermatology innovation across several conditions, including atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, epidermolysis bullosa, prurigo nodularis, and more.